Emmetrope Ophthalmics LLC, (aka “Emmecell”) is a privately-held, clinical stage biotechnology company developing cell-based therapies. Emmecell’s platform technology leverages magnetic nanoparticles to effectively localize and integrate cell therapies to the appropriate target tissue. Our lead product EO2002 is a cell therapy for treatment for corneal edema, the most common indication for corneal transplantation.
Cell Manufacturing and Production LLC (CellMP) was founded in 2018 and is a subsidiary of Emmecell providing GMP manufacturing services in Menlo Park, CA.
Company Details
- Employees
- 11
- Address
- 3475 Edison Way,
- in****@****ell.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- emmecell.com
- Keywords
- Biotechnology, Ophthalmology, Cell Therapy, Nanotechnology, Magnetic Cell Delivery, Clinical Trials, cGMP Manufacturing.
- HQ
- Menlo Park, California
Emmecell Questions
Emmecell's website is emmecell.com
Emmecell's LinkedIn profile is https://www.linkedin.com/company/emmecell
Emmecell has
11 employees.
View email and phone details for 11
employees at Emmecell.
Emmecell's industry is
Biotechnology Research
Emmecell's top competitors are
Milkomeda Capital,
Eversight,
Peripherex,
Twenty/twenty Therapeutics,
Denali Therapeutics,
Arc Institute,
Avellino,
Gigagen Inc,
Eyepoint,
Ocular Therapeutix, Inc..
Emmecell's support email address is info@emmecell.com
Emmecell's categories are Biotechnology Research
